These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16036424)

  • 1. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole.
    Paillisse C; Lacomblez L; Dib M; Bensimon G; Garcia-Acosta S; Meininger V
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Mar; 6(1):37-44. PubMed ID: 16036424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis.
    Turner MR; Bakker M; Sham P; Shaw CE; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):15-21. PubMed ID: 12061944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
    Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
    Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
    Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
    Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.
    Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE
    Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying drug therapies.
    Brooks BR; Sanjak M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():68-75. PubMed ID: 15512878
    [No Abstract]   [Full Text] [Related]  

  • 8. How useful are retrospective studies in evaluating therapeutic interventions?
    Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):3. PubMed ID: 12061942
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials in ALS: what did we learn from recent trials in humans?
    Meininger V
    Neurodegener Dis; 2005; 2(3-4):208-14. PubMed ID: 16909027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole and ALS therapy.
    Hugon J
    Wien Med Wochenschr; 1996; 146(9-10):185-7. PubMed ID: 8873431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
    Armon C; Guiloff RJ; Bedlack R
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Sep; 3(3):109-12. PubMed ID: 12495570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic categories for amyotrophic lateral sclerosis.
    Scotton WJ; Scott KM; Moore DH; Almedom L; Wijesekera LC; Janssen A; Nigro C; Sakel M; Leigh PN; Shaw C; Al-Chalabi A
    Amyotroph Lateral Scler; 2012 Oct; 13(6):502-8. PubMed ID: 22670880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glutamate antagonist].
    Shindo M
    No To Shinkei; 1998 Jul; 50(7):597-605. PubMed ID: 9739517
    [No Abstract]   [Full Text] [Related]  

  • 15. [Amyotrophic lateral sclerosis. Fatal diagnosis -- how still can be helped?].
    Stiefelhagen P
    MMW Fortschr Med; 2004 Nov; 146(47):16. PubMed ID: 15624649
    [No Abstract]   [Full Text] [Related]  

  • 16. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
    Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
    J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival.
    Vender RL; Mauger D; Walsh S; Alam S; Simmons Z
    Amyotroph Lateral Scler; 2007 Feb; 8(1):36-41. PubMed ID: 17364434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.
    Georgoulopoulou E; Fini N; Vinceti M; Monelli M; Vacondio P; Bianconi G; Sola P; Nichelli P; Mandrioli J
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):338-45. PubMed ID: 23373475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and survival pattern of 1,153 patients with amyotrophic lateral sclerosis: experience over 30 years from India.
    Nalini A; Thennarasu K; Gourie-Devi M; Shenoy S; Kulshreshtha D
    J Neurol Sci; 2008 Sep; 272(1-2):60-70. PubMed ID: 18550082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.